Table 1

Characteristics at the start of the study and reasons for withdrawal during the study

Demographic variables (mean±SD)
 Age (years)14954±1414052±15
 Gender (% female)14968.5%14065.0%
 BMI (kg/m2)10725±410426±4
Clinical variables (mean±SD)
 Swollen joint count (number)14914±613814±6
 Tender joint count (number)14815±713714±7
 VAS pain (mm)14353±2613547±25
 VAS general wellbeing (mm)14654±2213552±22
 Functional disability (HAQ)1191.30±0.71091.25±0.7
Laboratory values (mean±SD)
 ESR (mm/h 1st)14837±2713839±25
 Hb (mmol/l)1488.0±0.81408.0±0.8
 Creatinine (µmol/l)14674±1413873±13
 Creatinine clearance (ml/min)13698±27131101±28
 AST (U/l)14523±813523±8
 ALT (U/l)14722±1313921±12
  Male 4625±124921±9
 Rheumatoid factor (% positive)13466.412463.7
Medical history (N)
 Diabetes mellitus44
  Grade 14036
  Grade 21822
  Grade 3119
 Cardiovascular diseases710
Reasons for withdrawal (N)
 MTX toxicity168
 Ciclosporin toxicity101
 Loss of efficacy134
 Other or unknown1814
Ciclosporin use during follow-up (N)397
NSAID use at baseline (N)116110
  • Values are mean±SD or percentages.

  • * C-group, conventional treatment strategy group; I-group, intensive treatment strategy group.

  • ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase; BMI, body mass index, COPD, chronic obstructive pulmonary disease; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire (0–3, most functional disability); Hb, haemoglobin; MTX, methotrexate; N, number of patients with available data; NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale pain and general wellbeing (range 0–100 mm, worst score).